Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVT-Dox
- Development stage
- Preclinical
- Lead developer
- Ambrilia Biopharma
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TVT-Dox is an NGR-peptide-targeted liposomal formulation of doxorubicin developed by Ambrilia Biopharma for the treatment of various solid tumors. The drug utilizes an asparagine-glycine-arginine (NGR) peptide sequence to target a specific isoform of aminopeptidase N (CD13) that is overexpressed on the surface of tumor neovasculature. By delivering doxorubicin specifically to the tumor's blood supply, TVT-Dox acts as a targeted anti-angiogenic and cytotoxic therapy, aiming to enhance efficacy and reduce systemic toxicity compared to free doxorubicin or non-targeted liposomal formulations like Caelyx. Development reached the preclinical stage for indications including prostate, lung, and ovarian cancers.
- Other names
- NGR-peptide-targeted liposomal doxorubicin
02
Targets
ANPEP (Aminopeptidase N)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on TVT-Dox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVT-Dox.